Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00223145
Status:
UNKNOWN
Last Update Posted:
2022-05-23
First Post:
2005-09-13
Brief Title:
Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone
Sponsor:
Abdenour Nabid
Organization:
Université de Sherbrooke
Study Overview
Official Title:
Randomized Multicentre Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy 70 Gy and 76 Gy Versus Prostate Radiation Therapy Alone at 76 Gy
Status:
UNKNOWN
Status Verified Date:
2022-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PCS III
Brief Summary:
The hypothesis of the proposed study would be that due to the six months of total androgen blockade which would include neoadjuvant hormonal therapy for four months and concomitant hormonal therapy for two months with irradiation the investigators could reduce local failure rates for these two dosage levels namely 70 Gy and 76 Gy Since increasing the dose to the prostate also seems to reduce local relapse rates the results of the two hormonal therapy groups would be compared with the results of prostate irradiation at doses of 76 Gy This study would verify the possibility of compensating a six Gy dosage increase of radiation therapy with six months of hormonal therapy between the 70 Gy and 76 Gy groups who received hormonal therapy and also match these results with a dose escalation to the prostate of 76 Gy In the future this could result in more therapeutic choices such as reducing the doses of radiation therapy and consequently its related complications if hormonal therapy proves to be beneficial or rather to continue in the direction of dose escalation for this intermediate-risk patient group everything being correlated to the side effects of hormonal therapy and irradiation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DC-990-0049 | None | None | None |